Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

NCT05909683 | Active Not Recruiting Phase 3

• 2 other identifiers: MODIFY2022-502962-26-00
• Study Type: interventional
• Target: 190
• Locations: 1 country
• Sites: 15

Brief Summary

MODIFY is a randomized, open-labeled, and prospective study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to change the traditional approach for the management of severe infections by integrating the results of BCID2, Reveal Rapid AST, and PCT, to improve patients' outcomes. Early and precise identification of the underlying causative pathogen along with the fast acquisition of the antimicrobial sensitivity results may positively impact the uncontrolled antimicrobial prescription.

Conditions

Sepsis

Keywords

Severe infections; Antibiotics; Procalcitonin; Blood Culture Identification 2 Panel (BCID2); Reveal Rapid AST system

Outcome Measures

Primary Outcomes (1)

• The number of days under treatment with broad-spectrum antibiotics in the group receiving the MODIFY strategy compared to patients treated by standard of care.

  The number of days under treatment with broad-spectrum antibiotics in the group receiving the MODIFY strategy compared to patients treated by standard of care.

  Through study completion, an average of 2 years

Secondary Outcomes (11)

• Time to first change of antimicrobial modification

  Through study completion, an average of 2 years

• Time to the first sterile blood culture

  Through study completion, an average of 2 years

• The number of patients in whom no changes in administered antibiotics will apply.

  Through study completion, an average of 2 years

• At least 2-point decrease of baseline SOFA (Sequential organ failure assessment) score by day 7

  Through study completion, an average of 2 years

• 28-day mortality

  Through study completion, an average of 2 years

Study Arms (2)

Standard-of-care

SHAM COMPARATOR

These patients will receive antibiotics according to standard practice of the attending physicians. The central lab will feedback to attending physicians and investigators the results of the conventional blood cultures and AST according to the routine SOP. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. Antibiotics will be stopped according to the local standard practice. BCID2, Reveal Rapid AST and PCT will be performed in the samples of these patients, attending physicians will not be provided such information.

Other: Standard of Care

MODIFY strategy

EXPERIMENTAL

These patients will start antibiotics according to standard practice of the attending physicians. It is anticipated that attending physicians will be informed in maximum 5 hours after randomization about the results of BCID2 including carriage of resistance genes and of the Reveal Rapid AST in the case of Gram-negative isolates. Physicians and investigators receiving this information are obliged to change the empirically prescribed antibiotics according to the rule provided in Box 1. The attending physicians and investigators will be allowed to decide for any change of antimicrobial treatment based on the results of conventional blood cultures provided to them by the central lab or any other culture provided to them by their hospital. PCT will be measured on day 1 and then daily starting from day 5. Attending physicians will be advised to discontinue antimicrobials on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml.

Diagnostic Test: Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results.

Interventions

Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results. DIAGNOSTIC_TEST

After the patient's blood flask is flagged positive for bloodstream infection, the blood sample will be assessed in the BCID2 diagnostic test in order to identify the underlying pathogens the patient is infected with. After the identification, and in the presence of gram-negative bacteria, the sample will be assessed in the Reveal Rapid AST test to provide information about which antimicrobials the specific pathogens are sensitive to. When both the identification of the pathogen and the sensitivities are available, the central laboratory will inform the attending physicians, who are obliged to change the standard of care antimicrobial therapy administered based on the rule in Box1 of the protocol. Finally, based on the results of the procalcitonin (PCT) on the first day by day 5 when PCT value is less than 80% of the initial value or it remains below 0.5 ng/ml, the attending physicians should discontinue the antimicrobial therapy.

MODIFY strategy

Standard of Care OTHER

Standard of care practices of the specific study site. Antimicrobials will be administered based on the attending physicians' critical opinion, and discontinuation will be done based on the standard procedures of the study site.

Standard-of-care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female
• For women of child-bearing potential, willingness to avoid pregnancy during the study and agreement to notify investigator if pregnancy occurs.
• Age more than or equal to 18 years
• Patients who have completed their participation in another study for more than 30 days can be included in this study.
• Written informed consent provided by the patient or by their legal representative in case of patients unable to consent due to sepsis onset affecting their mental capacity.
• Sepsis defined by the Sepsis-3 definition; this is defined separately for community-acquired sepsis and for hospital-acquired sepsis. Community-acquired sepsis is defined as any SOFA score 2 points or more for patients admitted in hospital emergencies with community-acquired pneumonia (CAP), community-acquired acute pyelonephritis (AP) or community-acquired primary bacteremia (BSI). CAP, AP and BSI are considered community-acquired for patients who have no history of hospitalization lasting more than 2 days the last 90 days or who are not under hemodialysis or who are not residents of long-term care facilities. Hospital-acquired sepsis is defined as any SOFA score increase by 2 points or more from the admission SOFA score for patients with onset of hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), acute pyelonephritis (AP) or primary bacteremia (BSI) at least 48 hours after hospital admission. For patients with history of hospitalization lasting more than 2 days the last 90 days or who are under hemodialysis or who are residents of long-term care facilities and are admitted to hospital with HAP, VAP, AP and BSI the definition of hospital-acquired sepsis applies. In this case, the baseline SOFA score is considered as the known SOFA score before infection onset.
• Presence of one of the following infections: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), acute pyelonephritis (AP) and primary bacteremia (BSI).
• Positive blood culture

You may not qualify if:

• Failure to obtain written consent to participate
• Previous enrollment in this study within the past 90 days. Patients enrolled in another study will not be accepted.
• Patients receiving prolonged antibiotic therapies (e.g. endocarditis, implantable device-associated infection, cerebral/hepatic abscess, osteomyelitis, meningitis)
• Patients with severe infections due to viruses or parasites (e.g. Dengue, Toxoplasma gondii, Plasmodium spp.)
• Patients with infection due to Mycobacterium tuberculosis.
• Patients suffering from cystic fibrosis
• Severely immunocompromised patients such as a) patients with infection by the human immunodeficiency virus and with a CD4 count of less than 200 cells/mm3; b) neutropenic patients with less than 500 neutrophils/mm3; and c) patients with solid organ transplantation.

Sponsors & Collaborators

• Hellenic Institute for the Study of Sepsis: lead

Study Sites (15)

Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital

Athens, Attica, 11527, Greece

Location

New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital

Athens, Attica, 11527, Greece

Location

2nd Propaedeutic Department of Internal Medicine, Attikon University Hospital

Athens, Chaidari, 12462, Greece

Location

4th Department of Internal Medicine, Attikon University Hospital

Athens, Chaidari, 12462, Greece

Location

1st Department of Internal Medicine, General Hospital of Elefsina "Thriasio"

Athens, Elefsina, 19600, Greece

Location

2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

Alexandroupoli, Greece

Location

1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.

Athens, 11526, Greece

Location

1st Department of Internal Medicine- General Hospital of Athens GENNIMATAS

Athens, 11527, Greece

Location

3rd University Department of Internal Medicine, Sotiria Athens General Hospital

Athens, 11527, Greece

Location

1st Department of Internal Medicine - General Hospital of Athens Sismanoglio- Amalia Fleming

Athens, 15126, Greece

Location

3rd Department of Internal Medicine - General State Hospital of Nikaia "Saint Panteleimon" - West Attica General Hospital "Agia Varvara"

Athens, 18454, Greece

Location

Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital

Kifissia, 14564, Greece

Location

2nd Department of Internal Medicine, General Hospital of Piraeus "Tzaneio"

Piraeus, 18536, Greece

Location

1st University Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki

Thessaloniki, 54636, Greece

Location

Intensive Care Unit, Ippokrateion General Hospital

Thessaloniki, 54642, Greece

Location

MeSH Terms

Conditions

Sepsis; Infections

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Evangelos Giamarellos-Bourboulis, MD,PhD

  Hellenic Institute for the Study of Sepsis

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: According to protocol study intervention is not study drug administration; intervention includes two steps: modification of antibiotics administered; duration of antibiotic treatment. SOC patients will receive antibiotics according to standard practice of the attending physicians. MODIFY strategy group patients will start antibiotics according to standard practice. They will be informed after randomization about the results of BCID2, Reveal Rapid AST and PCT. Physicians and investigators receiving this information are obliged to change the empirically prescribed antibiotics (escalate, de- escalate or stop) aiming to improve patient outcomes. Exceptions to overrule this algorithm will be accepted for medically unstable patients.

Study Record Dates

• First Submitted: June 9, 2023
• First Posted: June 18, 2023
• Study Start: September 19, 2023
• Primary Completion: April 15, 2026
• Study Completion: April 15, 2026
• Last Updated: January 16, 2026

Record last verified: 2026-01

Locations

GR (15)